Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPI-287 in Refractory/Recurrent Neuroblastoma and Medulloblastoma
NCT01483820Phase 2Terminated
- Start
- Dec 2011
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abeotaxane in neuroblastoma and medulloblastoma. Primary endpoint: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. Started Dec 2011; status: terminated.
02
Drugs
abeotaxane
03
Conditions
neuroblastomamedulloblastoma
Beyond the preview
Go deeper on NCT01483820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01483820.